J. Post

发表

Substituted thiophene-anthranilamides as potent inhibitors of human factor Xa.

M. Adler, M. Whitlow, M. Morrissey, 2007, Bioorganic & medicinal chemistry.

A novel P2Y12 adenosine diphosphate receptor antagonist that inhibits platelet aggregation and thrombus formation in rat and dog models

C. Mallari, R. Vergona, W. Dole, 2007, Thrombosis and Haemostasis.

Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (I): in vitro effects on platelets.

J. Morser, I. Islam, Shendong Yuan, 2008, Thrombosis research.

Human primary renal cells as a model for toxicity assessment of chemo-therapeutic drugs.

A. Birkeland, D. Choy, M. Sullivan, 2006, Toxicology in vitro : an international journal published in association with BIBRA.

Anti-atherosclerotic effect of simvastatin depends on the presence of apolipoprotein E.

R. Vergona, W. Dole, B. Martin-McNulty, 2002, Atherosclerosis.

Cell-based assays for profiling activity and safety properties of cancer drugs.

A. Birkeland, M. Sullivan, J. Post, 2006, Journal of pharmacological and toxicological methods.

Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (II): pharmacodynamic and pharmacokinetic characterization.

R. Vergona, W. Dole, J. Morser, 2008, Thrombosis research.

Effects of ZK-807834, a novel inhibitor of factor Xa, on arterial and venous thrombosis in rabbits.

D. Abendschein, P. Eisenberg, R. Vergona, 2000, Journal of cardiovascular pharmacology.

Human in vitro pharmacodynamic profile of the selective Factor Xa inhibitor ZK-807834 (CI-1031).

D. Abendschein, D. Light, M. Sullivan, 2002, Thrombosis research.

Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3, 5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylgl y cine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme factor Xa.

M. Whitlow, D. Davey, K. Eagen, 1998, Journal of medicinal chemistry.

Discovery and characterization of a potent and selective non-amidine inhibitor of human factor Xa.

J. Morser, D. Light, M. Kochanny, 2003, Biochemical pharmacology.

Thiophene-anthranilamides as highly potent and orally available factor Xa inhibitors.

Bin Ye, David Light, Marc Adler, 2007, Journal of medicinal chemistry.

Design, synthesis, and in vitro biological activity of benzimidazole based factor Xa inhibitors.

M. Whitlow, M. Morrissey, S. Sakata, 2000, Bioorganic & medicinal chemistry letters.

Use of cultured cells of kidney origin to assess specific cytotoxic effects of nephrotoxins.

M E Sullivan, D. Choy, W Li, 2003, Toxicology in vitro : an international journal published in association with BIBRA.

Reduction of cardiac functional reserve and elevation of aortic stiffness in hyperlipidemic Yucatan minipigs with systemic and coronary atherosclerosis.

M. Halks-Miller, R. Vergona, P. Verhallen, 2002, Vascular pharmacology.

A dual-labeling method to quantify unscheduled DNA synthesis in primary cells.

D. Choy, M. Sullivan, J. Post, 2008, Journal of pharmacological and toxicological methods.